ArticleInternational orthopaedics2025
Tourniquet use in patients with sickle cell trait (SCT): Mediterranean or African ancestry influences complications, demonstrating a higher prevalence than control patients: matched study of nine hundred and forty SCT versus one thousand, two hundred and sixty three non-SCT patients.
Article in International orthopaedics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Tourniquet-less total knee arthroplasty does not negatively affect cement penetration: a double-blinded randomized controlled trial.International orthopaedics · 2025Trial
- Implant removal in orthopaedic surgery: far more than a resident's simple task.International orthopaedics · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeOne ongoing debate in orthopaedic surgery concerns using tourniquets in sickle cell trait (SCT) patients. SCT, a heterozygous carrier state of sickle cell disease (SCD), affects an estimated 300 million individuals globally with various genetic ancestries.
methodsA retrospective cohort study was conducted on 940 SCT patients and 1263 matched non-SCT controls who underwent limb surgeries using tourniquets between 1978 and 2018. Patient data were gathered from hospital records, blood bank information, and postoperative haemoglobin electrophoresis. Outcomes assessed included the incidence of venous thromboembolism (VTE), pulmonary embolism (PE), phlebitis, peripheral nerve impairment, and superficial infection. Covariates included age, sex, ethnicity, and diabetes status.
resultsAmong SCT patients, 75% were unaware of their carrier status at surgery. VTE incidence was significantly higher in SCT patients (10%) than non-SCT controls (2%), especially after prolonged tourniquet use and in upper limb procedures without anticoagulation. PE occurred in 3% of SCT patients, versus 1% in controls. Diabetes, more prevalent in SCT individuals (9% vs. 6%), further increased the complication risk. Tourniquet inflation time did not differ significantly between groups; however, neurologic complications and phlebitis were more common in SCT patients, particularly those with Mediterranean ancestry. Notably, SCT carriers of African and Mediterranean descent experienced higher complication rates than non-carriers, though complications were not confined to any single ancestry.
conclusionSCT is associated with an increased risk of thrombotic and neurologic complications during tourniquet, particularly in patients with undiagnosed SCT or diabetes and in procedures with extended ischaemia time. These results confirm the perception of SCT as a benign condition, but call for further clinical guidelines regarding tourniquet use in SCT carriers.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.